164 related articles for article (PubMed ID: 8081790)
41. Clinicopathologic analysis of acute vascular rejection cases after renal transplantation.
Shimizu T; Tanabe T; Omoto K; Ishida H; Tanabe K
Transplant Proc; 2012 Jan; 44(1):230-5. PubMed ID: 22310621
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic Biomarkers to Diagnose Acute Allograft Rejection After Liver Transplantation: Systematic Review and Meta-Analysis of Diagnostic Accuracy Studies.
Krenzien F; Keshi E; Splith K; Griesel S; Kamali K; Sauer IM; Feldbrügge L; Pratschke J; Leder A; Schmelzle M
Front Immunol; 2019; 10():758. PubMed ID: 31031758
[No Abstract] [Full Text] [Related]
43. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group.
Wiesel M; Carl S
J Urol; 1998 Jan; 159(1):28-33. PubMed ID: 9400430
[TBL] [Abstract][Full Text] [Related]
44. Graft outcome in patients with biopsy-proven chronic renal allograft rejection.
Peddi VR; Schroeder TJ; Weiskittel P; First MR
Transplant Proc; 1999; 31(1-2):1308-9. PubMed ID: 10083584
[No Abstract] [Full Text] [Related]
45. Predictors of renal transplant histology at three months.
Kuypers DR; Chapman JR; O'Connell PJ; Allen RD; Nankivell BJ
Transplantation; 1999 May; 67(9):1222-30. PubMed ID: 10342313
[TBL] [Abstract][Full Text] [Related]
46. Elevated biliary interleukin 5 as an indicator of liver allograft rejection.
Lang T; Krams SM; Berquist W; Cox KL; Esquivel CO; Martinez OM
Transpl Immunol; 1995 Dec; 3(4):291-8. PubMed ID: 8665147
[TBL] [Abstract][Full Text] [Related]
47. Applications and limitations of blood eosinophilia for the diagnosis of acute cellular rejection in liver transplantation.
Barnes EJ; Abdel-Rehim MM; Goulis Y; Abou Ragab M; Davies S; Dhillon A; Davidson B; Rolles K; Burroughs A
Am J Transplant; 2003 Apr; 3(4):432-8. PubMed ID: 12694065
[TBL] [Abstract][Full Text] [Related]
48. Is blood eosinophilia an effective predictor of acute rejection in living donor liver transplantation?
Kishi Y; Sugawara Y; Tamura S; Kaneko J; Akamatsu N; Togashi J; Makuuchi M
Transpl Int; 2005 Oct; 18(10):1147-51. PubMed ID: 16162101
[TBL] [Abstract][Full Text] [Related]
49. Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection.
Le Moine A; Flamand V; Demoor FX; Noël JC; Surquin M; Kiss R; Nahori MA; Pretolani M; Goldman M; Abramowicz D
J Clin Invest; 1999 Jun; 103(12):1659-67. PubMed ID: 10377172
[TBL] [Abstract][Full Text] [Related]
50. [Sequential monitoring of renal transplant with aspiration cytology].
Manfro RC; Gonçalves LF; de Moura LA
Rev Assoc Med Bras (1992); 1998; 44(2):87-93. PubMed ID: 9699324
[TBL] [Abstract][Full Text] [Related]
51. The importance of eosinophil cells in kidney allograft rejection.
Kormendi F; Amend WJ
Transplantation; 1988 Mar; 45(3):537-9. PubMed ID: 3279576
[TBL] [Abstract][Full Text] [Related]
52. Correlation between Banff classification, acute renal rejection scores, and reversal of rejection.
Gaber LW; Moore LW; Alloway RR; Flax S; Gaber AO
Transplant Proc; 1995 Feb; 27(1):1019. PubMed ID: 7878784
[No Abstract] [Full Text] [Related]
53. Clinical significance of eosinophils in suspicious or borderline renal allograft biopsies.
Emovon OE; King JA; Smith SR; Op't Holt C; McDonald F; Howell DN; Browne BJ
Clin Nephrol; 2003 May; 59(5):367-72. PubMed ID: 12779099
[TBL] [Abstract][Full Text] [Related]
54. Activation of eosinophils and fibroblasts assessed by eosinophil cationic protein and hyaluronan in BAL. Association with acute rejection in lung transplant recipients.
Riise GC; Scherstén H; Nilsson F; Ryd W; Andersson BA
Chest; 1996 Jul; 110(1):89-96. PubMed ID: 8681673
[TBL] [Abstract][Full Text] [Related]
55. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD.
Negewo NA; McDonald VM; Baines KJ; Wark PA; Simpson JL; Jones PW; Gibson PG
Int J Chron Obstruct Pulmon Dis; 2016; 11():1495-504. PubMed ID: 27445469
[TBL] [Abstract][Full Text] [Related]
56. Macrophage migration inhibitory factor expression in human renal allograft rejection.
Lan HY; Yang N; Brown FG; Isbel NM; Nikolic-Paterson DJ; Mu W; Metz CN; Bacher M; Atkins RC; Bucala R
Transplantation; 1998 Dec; 66(11):1465-71. PubMed ID: 9869087
[TBL] [Abstract][Full Text] [Related]
57. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies.
Woodle ES; Cronin D; Newell KA; Millis JM; Bruce DS; Piper JB; Haas M; Josephson MA; Thistlethwaite JR
Transplantation; 1996 Oct; 62(7):906-10. PubMed ID: 8878382
[TBL] [Abstract][Full Text] [Related]
58. A blinded retrospective analysis of renal allograft pathology using the Banff schema: implications for clinical management.
Dean DE; Kamath S; Peddi VR; Schroeder TJ; First MR; Cavallo T
Transplantation; 1999 Sep; 68(5):642-5. PubMed ID: 10507482
[TBL] [Abstract][Full Text] [Related]
59. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
[No Abstract] [Full Text] [Related]
60. Renal allograft rejection in children and young adults: the Banff classification.
Corey HE; Greenstein SM; Tellis V; Schechner R; Greifer I; Bennett B
Pediatr Nephrol; 1995 Jun; 9(3):309-12. PubMed ID: 7543274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
